# A Study of DS-3939a in Participants With Solid Tumors

Source: https://onco.cc/trials/nct07739966/  
OnCo record `nct07739966` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pembrolizumab, carboplatin and pemetrexed in lung cancer, run by Daiichi Sankyo, not yet recruiting.

## Summary

A Study of DS-3939a in Participants With Solid Tumors is a phase 1/2, interventional study registered as NCT07739966 by Daiichi Sankyo, with a registry enrolment figure of 400 participants, started 2026-10-01 and due to reach its primary completion in 2030-07-31. Interventions recorded: DS-3939a; Pembrolizumab; Carboplatin; Pemetrexed; DS-1103a. Conditions listed: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer. Primary outcome: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs); Part 1: Number of Participants With TEAEs; Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by Investigator. Lung eligibility wording from the registry: "Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07739966
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors
- Sponsor: Daiichi Sankyo
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07739966: https://clinicaltrials.gov/study/NCT07739966

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07739966.json